Epidemiological Features of the COVID-19 and Characteristics of Patients during the Spread of the Omicron SARS-COV-2 in Russia

Aim. To analyze dynamic of incidence and mortality of COVID-19 and clinical and epidemiological characteristics of adult patients with a new coronavirus infection during the early period of the Omicron SARS-COV-2 distribution in Russia. Materials and Methods. We conducted a retrospective analysis of the dynamics of COVID-19 incidence and mortality in Russia until 2023. Study included patients aged ≥18 years with a laboratory-confirmed diagnosis of COVID-19, detected in the period from 01/02/2022 to 14/03/2022 (n = 3 582 688) in 85 regions of Russia. Participants were included regardless their COVID-19 vaccination history. Results. We identified 6 periods of rise and decline in the COVID-19 incidence until 2023 in Russia. The 5th (January–July 2022) and the 6th (August-November 2022) periods were associated with the spread of the Omicron SARS-CoV-2. The median age of patients in the early period of Omicron spreading was 49 (36–62) years, 62.7% were women. The largest proportion of patients were represented by the age groups 30–39 and 40–49 years (19.2% each), the lowest – 18–29 years (12.3%). Proportion of patients with mild disease was 90.0%, moderate – 8.5%, severe – 0.9%, extremely severe – 0.6%. Hospitalization rate, proportion of patients treated in the intensive care unit and rate of invasive mechanical ventilation were 7.6%, 9.5% and 6.7% respectively. The median period from the onset of symptoms to the diagnosis was 2 (1–3) days, median of duration of the disease was 8 (6-10) days and median duration of hospitalization was 10 (7–14) days. The median age of the deceased patients was 77 (69–84) years, of which 50.8% were women, 72.6% were persons ≥70 years old. One or more concomitant diseases were detected among 8.7% of patients who became ill and 75.8% of those who died. The probability of hospitalization, admission to the ICU, IMV and death in patients with one or more concomitant diseases were 24.5, 3.2, 3.5 and 35.8 times higher, respectively, compared with patients without concomitant diseases. Conclusion. In the early period of the spread of the Omicron variant in Russia, among adult patients with COVID-19, excluding their vaccine history, the frequency of severe and extremely severe forms of infection was 1.5%. The elderly age and the presence of concomitant diseases remained key risk factors for the development of adverse outcomes of the COVID-19

1. Gao L, Zheng C, Shi Q, et al. Evolving trend change during the COVID-19 pandemic. Front Public Health. 2022;10:957265. doi:10.3389/fpubh.2022.957265.

2. Karpova LS, Komissarov AB, Stolyarov KA, et al. Features of the COVID-19 Epidemic Process in Each of the of the Five Waves of Morbidity in Russia. Epidemiology and Vaccinal Prevention. 2023;22(2):23–36. (In Russ.). doi: 10.31631/2073-3046-2023-22-2-23-36

3. Platonova T.A., Golubkova A.A., Smirnova S.S., et al. COVID-19 epidemic process in the Russian Federation: determinants and manifestations. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2023;12(3):8–17. (In Russ.). doi: 10.33029/2305-3496-2023-12-3-8-17

4. World health organization [Internet]. Historical working definitions and primary actions for SARS-CoV-2 variants. Available at: https://www.who.int/publications/m/item/historical-working-definitions-and-primary-actions-for-sars-cov-2-variants. Accessed: 1 Apr 2024.

5. Chatterjee S, Bhattacharya M, Nag S, et al. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses. 2023;15:167. doi:10.3390/v15010167.

6. Jung C, Kmiec D, Koepke L, et al. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? Virol J. 2022;96(6):e0207721. doi:10.1128/jvi.02077-21.

7. Meo SA, Meo AS, Al-Jassir FF, et al. Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012–8018. doi:10.26355/eurrev_202112_27652.

8. Xia S, Wang L, Zhu Y, et al. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct Target Ther. 2022;7:241. doi:10.1038/s41392-022-01105-9.

9. Liu W, Huang Z, Xiao J, et al. Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness. Viruses. 2024;16(2):184. doi:10.3390/v16020184.

10. Tallei TE, Alhumaid S, AlMusa Z, et al. Update on the omicron sub-variants BA.4 and BA.5. Rev Med Virol. 2023;33(1):e2391. doi:10.1002/rmv.2391.

11. Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738– 1744. doi:10.1002/jmv.27524.

12. Manathunga SS, Abeyagunawardena IA, Dharmaratne SD. A comparison of transmissibility of SARS-CoV-2 variants of concern. Virol J. 2023;20(1):59. doi: 10.1186/s12985-023-02018-x.

13. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602(7898):682–688. doi: 10.1038/s41586-022-04399-5.

14. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e15. doi:10.1016/j.cell.2021.12.046.

15. Lapa D, Grousova DM, Matusali G, et al. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines (Basel). 2022;10(5):817. doi: 10.3390/vaccines10050817.

16. Sizikova T.E., Chuhralya O.V., Lebedev V.N., et al. The Omicron Variant of SARS-CoV-2 Virus: the Ability to Cause Disease in Persons with Immunity against COVID-19. Journal of NBC Protection Corps. 2022;6(1):44–55. (In Russ.). doi:10.35825/2587-5728-2022-6-1-44-55

17. Jacobsen H, Katzmarzyk M, Higdon MM, et al. Post-Vaccination Neutralization Responses to Omicron Sub-Variants. Vaccines (Basel). 2022;10(10):1757. doi:10.3390/vaccines10101757.

18. Barchuk A, Bulina A, Cherkashin M, et al. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: A test-negative case-control study. Respir Res. 2022;23(1):276. doi:10.1186/s12931-022-02206-3.

19. Yang W, Yang S, Wang L, et al. Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China. Virol Sin. 2022;37(5):704–715. doi:10.1016/j.virs.2022.07.014.

20. Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556. doi:10.1016/j.lanepe.2022.100556.

21. Klink GV, Danilenko D, Komissarov AB, et al. An Early SARS-CoV-2 Omicron Outbreak in a Dormitory in Saint Petersburg, Russia. Viruses. 2023;15(7):1415. doi:10.3390/v15071415.

22. CoVariants [Internet]. Overview of Variants in Countries. Available at: https://covariants.org/per-country. Accessed 1 Apr 2024.

23. Briko NI, Korshunov VA, Krasnova SV, et al. Clinical and epidemiological characteristics of hospitalized patients with COVID-19 during different pandemic periods in Moscow. Journal of microbiology, epidemiology and immunobiology. 2022;99(3):287–299. (In Russ.). doi:10.36233/0372-9311-272.

24. Gushchin VA, Pochtovyi AA, Kustova DD, et al. Characterisation of the COVID-19 epidemic process in Moscow and search for possible determinants of the trends of the observed changes. Journal of microbiology, epidemiology and immunobiology. 2023;100(4):267–284. (In Russ.). doi:10.36233/0372-9311-375.

25. Niu Y, Luo L, Yang S, et al. Comparison of epidemiological characteristics and transmissibility of different strains of COVID-19 based on the incidence data of all local outbreaks in China as of March 1, 2022. Front Public Health. 2022;10:949594. doi:10.3389/fpubh.2022.949594.

26. Tang S, Wang X, Tang B, et al. Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China. BMC Public Health. 2023;23(1):1084. doi:10.1186/s12889-023-16009-8.

27. Lee K-S, Go MJ, Choi YY, et al. Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service. PLoS One. 2024;19(3):e0300306. doi:10.1371/journal.pone.0300306.

28. Hu F-H, Jia Y-J, Zhao D-Y, et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Clin Microbiol Infect. 2023;29(7):835–844. doi:10.1016/j.cmi.2023.03.017.

29. Colnago M, Benvenuto GA, Casaca W, et al. Risk Factors Associated with Mortality in Hospitalized Patients with COVID-19 during the Omicron Wave in Brazil. Bioengineering. 2022;9(10):584. doi:10.3390/bioengineering9100584.